Chemical name | Trade name in the United States | Vendor | Ligand class | Net charge | Tissue distribution | Biliary excretion |
Group I: Associated with highest number of cases of nephrogenic systemic fibrosis | ||||||
Gadodiamide | Omniscan | GE Healthcare | Linear | Nonionic | Extracellular | None |
Gadopentetate dimeglumine | Magnevist | Bayer HealthCare Pharmaceuticals | Linear | Ionic | Extracellular | None |
Gadoversetamide | OptiMARK | Covidien | Linear | Nonionic | Extracellular | None |
Group II: Associated with few or no unconfounded cases* of nephrogenic systemic fibrosis | ||||||
Gadobenate dimeglumine | MultiHance | Bracco Diagnostics | Linear | Ionic | Extracellular | 3% |
Gadobutrol | Gadavist¶ | Bayer HealthCare Pharmaceuticals | Macrocyclic | Nonionic | Extracellular | None |
Gadoterate meglumine | Dotarem | Guerbet | Macrocyclic | Ionic | Extracellular | None |
Gadoteridol | Prohance | Bracco Diagnostics | Macrocyclic | Nonionic | Extracellular | None |
Group III: Limited number of administrations with no cases of nephrogenic systemic fibrosis | ||||||
Gadofosveset trisodiumΔ | Ablavar | Lantheus Medical Imaging | Linear | Ionic | Blood pool | None |
Gadoxetate disodium | Eovist | Bayer HealthCare Pharmaceuticals | Linear | Ionic | Hepatocellular | 50% |